• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support
            • North & South America
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management
            • Study Start-up & Feasibility
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management
            • Patient Recruitment
            • Personalized Clinical Trial Operations
            • Biometrics
            • Medical & Safety Monitoring
            • Clinical Data Management
            • Medical Writing
        • Clinical Development Strategy
            • Clinical Development Planning
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies
            • Cell & Gene Therapy Strategies
            • CDx Regulatory and Market Access
        • Clinical Trial Design
            • Basket & Umbrella Trials
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials
            • Master Protocol Trials
            • Decentralized Clinical Trials
        • Biostatistics
            • Statistical Consulting
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design
            • Data Monitoring Committees
            • CDISC Programming and Documentation
            • eCTD Submissions
        • Central Lab Services
            • Clinical Specimen Kitting
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing
            • Global Specimen Logistics and Biostorage
            • Biospecimen Data Services
            • Precision Lab e-Portal
            • Virtual Sample Inventory Management
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services
            • Clinical Specimen Kitting
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing
            • Global Specimen Logistics and Biostorage
            • Biospecimen Data Services
            • Precision Lab e-Portal
            • Virtual Sample Inventory Management
        • Specialty Lab Services Overview
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization
        • Immune Monitoring
            • Immune Monitoring by Flow Cytometry
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID
            • Cytokine Profiling
            • Gene Expression Profiling
            • ELISpot and FluoroSpot
            • Custom Assays
        • Flow Cytometry
            • Receptor Occupancy Assays by Flow Cytometry
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

        • Genomics
            • NanoString Assays
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR
            • qPCR
            • NGS
            • Fluorescence In Situ Hybridisation (FISH) / ISH
        • Tissue & Liquid Biopsy
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis
            • Multiplex Immunofluorescence
            • Immunohistochemistry
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services
            • NanoString Assays
        • Bioanalytical Testing
            • Immunogenicity Testing
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays
            • ADA Assays
            • MesoScale Discovery (MSD) Assays
            • Quanterix SIMOA
            • ELISA
        • Protein & Cytokine Analysis
            • ELISA
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex
            • Quanterix SIMOA
            • Automated Western Blotting
        • Preclinical Target and Biomarker Validation
            • Cell Based Assays
            • Target Expression – XpressWay Profiles
            • Tissue Cross-Reactivity
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Multiplex Immunofluorescence
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • QuartzBioImage

                QuartzBio® Solutions


                Purpose-built SaaS solutions developed to address the complex, manual, and siloed processes that exist in sample and biomarker data management by delivering innovative data-enabling technologies in a single, scalable platform.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio® Solutions
            • enterprise Biomarker Data Management (eBDM)
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • virtual Sample Inventory Management (vSIM)
            • Analytics, Information, Insights, and Reporting
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Companion Diagnostics
    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
        • By Research Phase
        • Preclinical Development
        • Early Phase Trials (I-IIa)
        • Late Phase Trials (IIb-III)
    • News &
      Insights
        • Blog
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources
        • Thought Leadership
        • News
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People
        • Careers
        • Regulatory Information
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    ✕
    • Home
    • High-Quality Biospecimens in Therapeutic & Diagnostic Development: A Comprehensive Guide from Concept to Cloud
    Blog Clinical Research Insights Translational & Lab Insights
    Article

    High-Quality Biospecimens in Therapeutic & Diagnostic Development: A Comprehensive Guide from Concept to Cloud

    Written By Amanda Woodrooffe, PhD, Robert Snyder, PhD
    August 16, 2023 • 9 min. read

    Precision Medicine and the Rising Importance of High-Quality Biospecimens

    Human biospecimens are essential for advancing scientific research across the entire continuum of preclinical and clinical drug development. In this era of precision medicine, high-quality biospecimens play a critical role as essential resources for target identification, biomarker discovery research, and therapeutic development strategies. They play a pivotal role in assay development and validation, enabling researchers to conduct molecular and cellular analysis that inform personalized treatment strategies.

    Here, we focus on the use of biospecimens for tissue-based analyses at different stages of development, leveraging real-life examples to demonstrate how well-annotated samples can be used to generate actionable data from bench to bedside and back, creating endless value.

    The Biospecimen Journey: From Preclinical Histology to Clinical Studies in Drug Development

    In preclinical development, it is common to apply histology, immunohistochemistry (IHC), and genomic analysis to interrogate tissues or biopsy samples. These techniques allow researchers to gain comprehensive insight into disease biology, pathophysiology, and the molecular mechanisms underpinning various conditions. This information is critical for drug discovery and development processes.

    Recommended Reading

    Strategies to Support Successful Translation of Preclinical Biomarker Assays

    Alzheimer’s Disease Case Study: The Impact of Quality Biospecimens

    Precision for Medicine was engaged to develop a well-characterized tissue microarray (TMA) to support groundbreaking Alzheimer’s disease (AD) research, utilizing quality-controlled and ethically sourced biospecimens. In addition to our tissue analysis capabilities and deep experience in supporting central nervous system (CNS) disease research, Precision for Medicine has access to a range of sample types across a range of CNS diseases through a strong, longstanding partnership with a European brain bank.

    Access To Diseased CNS TissuesCNS Tissue Analysis Capabilities
    • Alzheimer’s Disease

    • Parkinson’s Disease

    • Frontotemporal dementia

    • Dementia – Lewy Body Variant

    • Multi system atrophy

    • Multiple Sclerosis

    • Amyotrophic lateral sclerosis

    • Progressive Supranuclear Palsy

    • Pick’s Disease

    • Pain
    • mRNA expression analysis

    -Quantitative RT-PCR
    -In situ hybridization (RNAscope)

    • Protein expression analysis

    -Immunohistochemistry
    -Multiplexed immunofluorescence
    -Western blot (automated – Biotechne JESS)

    • Protein isolation / enrichment

    -PHF-Tau
    -Alpha-synuclein

    The objective of the TMA was to investigate target and biomarker expression across the staged progression of AD. To achieve this, we worked collaboratively with our brain bank partner to source temporal cortex tissue from patients with early (Braak I and II) , mid (Braak III and IV), and late (Braak V and VI) stage AD and select samples based on additional factors such as amyloid score, apolipoprotein E (APOE) genotype data, cerebrospinal fluid (CSF) pH, and clinical history. We then created a TMA comprising tissues from five individual donors per stage and five non-disease donors.

    Recommended Reading

    Advancing the Use of Biomarkers in CNS Drug Discovery and Development

    The resulting TMA was qualified using immunohistochemistry (IHC) for expression of hallmark disease markers: phosphorylated tau (phospho-tau or p-tau) and amyloid beta (Aβ) 1-42, a hyperphosphorylated form of Aβ (see Figure 1). Both p-tau and Aβ 1-42 expression were found to increase with Braak stage in the TMA.

    Figure 1. Qualification of TMA using IHC for expression of p-tau

    To enhance the clinical relevance of the study, the TMA was further characterized by investigating two glial markers, IBA-1 for microglia and GFAP for astrocytes, highlighting the role of quality biospecimens in neurodegenerative disease research. Both microglia and astrocytes undergo changes in frequency and morphology in different stages of AD, as seen for both IBA-1and GFAP in Figure 2.

    Figure 2. Changes in staining intensity and cell morphology at different stages of AD

    To take it even further, digital pathology and AI-powered image analysis allow simultaneous evaluation of staining patterns in matched fields of view. These advanced technologies enable the precise detection and quantification of potential targets and biomarkers, allowing for deeper insights into their association with specific cell populations. This is a fundamental step in translational medicine, bridging laboratory findings to clinical applications. (see Figure 3).

    Figure 3. Evaluation of staining patterns in matched fields of view shows overlapping distribution of hallmark disease and glial markers and dense aggregation of GFAP immunoreactive astrocytes in the location of a suspected plaque

    Case Study: Immuno-Oncology and the Detailed Interrogation of Tissue with Multiplex Immunofluorescence (mIF)

    Complex diseases and target organ structures often require extremely detailed interrogation of the tissue to yield insights into disease biology or assess drug efficacy or safety. While tissue biopsies are invasive, they enable localized analysis of protein biomarkers and topographic investigation of disease- and drug-related changes. In recent years, spatial analysis of multiple tissue biomarkers using multiplex immunofluorescence (mIF) has become routine for generating or supporting exploratory data during clinical development, especially in conditions with core immune components, such as cancer and inflammatory or autoimmune diseases.

    Importantly, mIF maximizes that data that can be extracted from a very limited amount of tissue, whether from a preclinical animal model or a clinical biopsy sample. mIF can interrogate multiple markers on a single slide, generative quantitative data on cell counts, intensity, co-localization, and even spatial localization.

    For instance, Precision for Medicine developed multiplex immunofluorescence (mIF) panels to meticulously characterize various mouse tumor models, demonstrating the power of precise tissue analysis in oncology research. Using the assays developed, we were able to characterize post-treatment changes in target expression and in the tumor microenvironment using animal model samples and then translate those learnings to human tissue-based assays to support exploratory biomarker evaluation in early clinical development.

    Transitioning to a Clinical Assay: Considerations and Challenges

    Transitioning from preclinical tissue-based analyses to assays that might be more applicable in the clinical development setting requires consideration of several factors, including:

    • Accessible sample types
    • The sample collection process
    • The logistics of transporting samples from multiple clinical sites to either a central or specialty lab for downstream analysis

    In CNS conditions, a key driver for assay development is the need for either less- or non-invasive means for biomarker analysis, diagnosis, patient selection or stratification, or disease monitoring. While CSF is an optimal source for biomarkers given its direct relation to the extracellular space in the brain, it is more invasive than imaging- or blood-based approaches. In AD, modalities such as improved positron emission tomography (PET) imaging tracers for detecting Aβ and tau pathology and blood- or exosome-based biomarkers are well-suited for clinical applications. Researchers are also:

    • Utilizing data garnered from AD biomarker measurements in the brain to identify predictive blood biomarkers and even correlate those blood biomarker levels with cognitive function
    • Examining biomarker combinations that can differentiate between stages of AD with greater specificity and sensitivity
    • Developing machine learning techniques from CSF proteomic profiles to identify potential biomarkers that can predict rates of cognitive decline

    Development of any of these assays, especially those leveraging liquid biopsies, to correlate back to brain pathology relies on access to the right biospecimens. These specimens, which must be ethically sourced and rigorously quality-controlled, support basic research, proof of concept studies, and the broader goals of personalized medicine and targeted therapies.

    In the immuno-oncology space, Precision for Medicine developed a fit-for-purpose assay for immune cell profiling in non-small cell lung cancer (NSCLC). To qualify this assay, we looked at tissue samples from three individual donors with NSCLC, using three slides from each donor and investigated three matched regions of interest per slide to assess consistency of both the cell counts and the percentage of target-expressing cells. We were able to demonstrate that intra-donor data were highly consistent for the targets of interest (see Figure 4) and the assay was appropriate to apply to a clinical trial cohort.

    Figure 4. Fit-for-purpose mIF assay for immune cell profiling in NSCLC generates reliable, high content data

    Given that there is inter-individual variability in tumor target expression, patient selection and predictive biomarkers may require large tissue cohorts for establishment of an expression level cut point. Being able to readily access well-annotated samples to support these assay validations is imperative.

    Case Study: Custom IHC Assay Development for Clinical Trial Enrollment in Oncology

    To support enrollment in a global Phase 1 oncology study, Precision for Medicine developed and validated a custom IHC assay, reagent kit, and scoring index (SI) for assessing P-cadherin, a cellular adhesion protein that contributes to oncogenesis. The SI was based on the tumor area stained multiplied by the staining intensity (see Figure 5). Patients whose tumor biopsies had an SI of 4 or higher were eligible for enrollment.

      Figure 5. Development of a custom IHC assay and scoring index for enrollment into a Phase 1 study

    Expanding Access to Well-Characterized Biospecimens for Assay Validation

    Validation of clinical trial assays requires the right biospecimens. Critical bottlenecks in the assay validation process are:

    1. Finding and accessing samples positive for the biomarker of interest
    2. Getting orthogonal confirmation for positive and negative calls

    In 2020, Precision for Medicine launched the Precision Oncology Sequencing Initiative (Project POSI), a next generation sequencing (NGS) program focused on genetically characterizing as many of the millions of oncology FFPE samples and histology slides in our biorepository as possible and banking these characterized samples for future use. We have adopted a platform- and assay-agnostic approach to sequencing, instead aiming to leverage the most useful and appropriate technology for generating oncology insights.

    Through partnerships, Precision for Medicine has characterized nearly 12,000 FFPE samples across over 15 cancer indications. More than 10,000 FFPE samples across 11 oncology indications have been characterized using, a targeted amplicon-based 50-gene panel that screens for single nucleotide variants (SNVs), indels, fusions, and amplifications. An additional 800 FFPE samples are being sequenced per month using a pan-cancer 500+ gene capture-based panel for tumor mutational burden (TMB), microsatellite instability (MSI), SNVs, indels, copy number variations (CNVs), fusions, and splice variants for verification, validation, and generation of orthogonal data for regulatory submissions.

    Precision for Medicine also has approximately 350 donors enrolled in a liquid biopsy sequencing initiative, which involves prospective collections under IRB-approved protocols that allow us to perform repeat or longitudinal biopsies as additional needs arise.

    For researchers, having access to our comprehensive and easily searchable database of ethically sourced and quality-controlled biospecimens, complete with NGS characterization and associated variant data, significantly streamlines the assay development process in precision medicine. Precision for Medicine also offers objective third-party orthogonal testing services for validating inter-laboratory reproducibility to support enrollment, predictive biomarkers, and companion diagnostic development.

    The Future of Pathology: Digital Solutions and Artificial Intelligence (AI)

    With the volume of pathology work required to support target and biomarker discovery and assay validation, keeping track of all the data generated and having a robust audit trail is crucial. At Precision for Medicine, we have onboarded Halo AP from Indica Labs to manage our pathology data and workflow. This cloud-based solution also enables multiple pathologists to collaborate, independent of geography.

    Taking it a step further, pathology data sets like ours are highly sought after for training artificial intelligence (AI) and machine learning. To that end, we have scanned hematoxylin and eosin (H&E)-stained slides of every NGS sample to supplement the physical tissue block, residual extracted DNA and RNA, variant data, and demographic information available. These high-resolution digital pathology images serve as robust training sets for machine learning algorithms, unlocking the potential to detect novel targets and biomarkers, thereby automating the discovery process and transitioning it into cloud-based platforms for global collaboration.

    Conclusion: The Integrated Approach of Precision for Medicine

    Precision for Medicine is a global precision medicine clinical research organization (CRO) that integrates clinical trial execution, specialty assay development, custom central lab services, advanced data sciences, and comprehensive biospecimen management solutions. With a focus on oncology, neurology, and complex diseases, we are committed to advancing patient-centric healthcare through cutting-edge molecular diagnostics and targeted treatments. We have seven labs globally, delivering a range of biomarker assays that interrogate the full spectrum of analytes in biofluids, cells, and tissues.

    We also have millions of IRB-approved, clinically-annotated biospecimens and actively manage custom prospective collections across multiple sample types and formats, uniquely positioning us to offer an end-to-end solution for integrating biomarkers and biospecimens from concept to clinic to cloud.

    Figure 6. The pivotal role of high quality biospecimens throughout the continuum of development

    Discover how our high-quality biospecimens are the key to driving successful therapeutic and diagnostic development. Watch our on-demand webinar now and take the next step towards groundbreaking healthcare innovation.


    • Amanda Woodrooffe, PhD

      Amanda Woodrooffe, PhD. is an experienced leader of scientific operations for drug discovery in both the pharmaceutical and CRO industries.  She is driven to provide actionable data enabling biopharmaceutical research and development. Collaborative partner ensuring licensing and scientific support for corporate development initiatives.

    • Robert Snyder, PhD

      Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside.

    Related Posts

    Choosing the Optimal Sample Type for Flow Cytometry: Key Considerations and Case Studies

    Angelina B., Deborah P.

    Jun 22, '23 · 6 min. read

    Moving from Exploratory to Clinical Flow Cytometry Assays: 3 Critical Considerations

    Deborah Phippard, PhD

    May 31, '23 · 4 min. read

    Guiding Precision Medicine with Liquid Biopsy: Circulating DNA vs Circulating Tumor Cells

    Jesus Garcia, PhD

    May 03, '23 · 9 min. read

    Harnessing the Power of Flow Cytometry in Biomarker-Driven Clinical Trials

    Laura Lozzo, PhD

    Apr 19, '23 · 5 min. read

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR